Lung Cancer Considered
Science & Technology News
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda
Location:
United States
Genres:
Science & Technology News
Description:
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda
Language:
English
Website:
https://www.iaslc.org/
Episodes
FDA Approval: Maintenance Lurbinectedin for SCLC
10/7/2025
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC. Guest: Dr. Hossein Borghaei, DO, MS Chief, Division of Thoracic Medical Oncology Professor, Department of Hematology/Oncology Fox Chase Cancer Center
Duration:00:37:53
Lung Cancer Considered: Targeting EGFR NSCLC
10/3/2025
Lung Cancer Considered: Targeting EGFR NSCLC by IASLC
Duration:00:44:06
Lung Cancer Considered in Dutch: Targeting EGFR NSCLC
10/3/2025
As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Lizza Hendriks moderates a discussion in Dutch with Dr. Marthe Paats and Dr. Gerrina Ruiter on the treatment of EGFR non-small cell lung cancer.
Duration:00:44:06
Lung Cancer Considered in Japanese---2025 WCLC Highlights
10/2/2025
Lung Cancer Considered in Japanese---2025 WCLC Highlights by IASLC
Duration:00:34:51
LCC in Korean: WCLC 2025 Highlights
9/30/2025
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Min Hee Hong. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Instagram: @fe0120 Guest Name(s) & Title(s): Jeongmin Seo, MD, MSc Assistant Professor, Medical Oncology Seoul National University Bundang Hospital Min Hee Hong, MD Associate Professor, Yonsei Cancer Center Severance Hospital, Seoul
Duration:00:20:24
IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy
9/26/2025
IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy by IASLC
Duration:00:45:40
LCC in Mandarin: WCLC 2025 Highlights with Experts from Taiwan
9/18/2025
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, guest host Dr. Kuan Yu Chen moderates a discussion in Mandarin with Dr. Bin-Chi Liao and Dr. Jeng-Sen Tseng, leading lung cancer experts in Taiwan, who share their perspectives on key highlights from the conference.
Duration:00:49:37
LCC in Portuguese: WCLC 2025 Highlights
9/16/2025
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Clarissa Baldotto, Dr. Lilian Faroni, Dr. Maria Cecilia Mathias, and Dr. William William, Jr.
Duration:00:42:45
LCC in Spanish: WCLC 2025 Through a Junior Faculty Lens
9/11/2025
In this episode, recorded live in Spanish at WCLC 2025, Dr. Diego Carrillo reflects on his experiences as a junior faculty member at WCLC 2025. In conversation with host Dr. Narjust Florez, they discuss conference activities, research highlights, and how WCLC helps junior faculty build their networks and shape the future of lung cancer care and research.
Duration:00:23:02
LCC in Hebrew: WCLC 2025 Highlights
9/10/2025
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Alona Zer moderates a discussion in Hebrew about highlights from the conference with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel.
Duration:00:19:47
Live From WCLC 2025: Tuesday Highlights & Meeting Summary
9/9/2025
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.
Duration:00:43:49
LCC in Spanish: WCLC 2025 Highlights
9/9/2025
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about highlights from the conference with Dr. Laura Mezquita and Dr. Jorge Alatorre Alexander.
Duration:00:40:07
Live From WCLC 2025: Monday Highlights
9/8/2025
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.
Duration:00:42:29
LCC in Mandarin: WCLC 2025 Highlights
9/8/2025
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.
Duration:00:35:32
Live From WCLC 2025: Sunday Highlights
9/7/2025
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.
Duration:00:24:29
"I'm in Barcelona, Now What?" — Tips for First-Time WCLC Attendees
9/6/2025
In this episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu share tips for first-time attendees of the World Conference on Lung Cancer (WCLC). Recorded live at WCLC 2025, hear their 10 key recommendations to make the most of your experience, including advice on how to sneak self-care into your busy conference schedule.
Duration:00:19:07
LCC in Mandarin: Neoadjuvant and Perioperative Therapy for Locally Advanced NSCLC
8/29/2025
LCC in Mandarin: Neoadjuvant and Perioperative Therapy for Locally Advanced NSCLC by IASLC
Duration:00:52:17
IASLC - ALK Positive Summit
8/26/2025
IASLC - ALK Positive Summit by IASLC
Duration:00:38:16
LCC in Greek: Virtual Tumor Board - ALK NSCLC
8/22/2025
LCC in Greek: Virtual Tumor Board - ALK NSCLC by IASLC
Duration:01:00:42
Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy
8/19/2025
Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy by IASLC
Duration:00:53:26